Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

66.89 -1.16 (-1.70%)
Streaming Delayed Price Updated: 2:17 PM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 681,118
Open 68.04
Bid (Size) 66.86 (200)
Ask (Size) 66.93 (200)
Prev. Close 68.05
Today's Range 66.75 - 68.84
52wk Range 47.50 - 82.22
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Cash-Producing Stocks with Exciting Potential
Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain ... 
Via StockStory
News headline image
2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory

Performance

YTD
-4.9%
-4.9%
1 Month
+4.1%
+4.1%
3 Month
-8.3%
-8.3%
6 Month
+0.8%
+0.8%
1 Year
+9.2%
+9.2%

More News

Read More
News headline image
1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off
Via StockStory
News headline image
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Reports Mixed Q4 2025 Results with Revenue Beat and Unexpected Loss ↗
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): A GARP Stock with Strong Growth and Reasonable Valuation ↗
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth and Technical Setup ↗
Via Chartmill
News headline image
2 Reasons to Like HALO (and 1 Not So Much)
Via StockStory
Topics Stocks
News headline image
Halozyme (HALO) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales
Via StockStory
Halozyme Therapeutics Inc (NASDAQ:HALO) Passes Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
News headline image
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know
Via StockStory
Topics Economy
News headline image
3 Small-Cap Stocks with Solid Fundamentals
Via StockStory
Topics Government
News headline image
3 Growth Stocks Set to Flourish
Via StockStory
News headline image
A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack
Via StockStory
Topics Artificial Intelligence
News headline image
Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
HALO Stock Edges Up 3% On Upbeat Multi-Year Revenue Guidance, Surf Bio Acquisition ↗
Via Stocktwits
News headline image
Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR)
Via StockStory
Topics Artificial Intelligence
News headline image
Q3 Rundown: Amgen (NASDAQ:AMGN) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
Via The Motley Fool
Topics ETFs Intellectual Property World Trade
News headline image
Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX)
Via StockStory
Topics Artificial Intelligence
News headline image
Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty ↗
Via The Motley Fool
News headline image
Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks
Via StockStory
Topics Artificial Intelligence

Frequently Asked Questions

Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
The current price of Halozyme Therapeutics, Inc. - Common Stock is 66.89
When was Halozyme Therapeutics, Inc. - Common Stock last traded?
The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 04/16/26 02:17 PM ET
What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 9.52B
How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
Halozyme Therapeutics, Inc. - Common Stock has 10B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.